Open Access<p>First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research</p>
Author(s) -
Federica Tomao,
Serena Maria Boccia,
Carolina Maria Sassu,
Martina Chirra,
Innocenza Palaia,
Maria Cristina Petrella,
Violante Di Donato,
Nicoletta Colombo,
Pierluigi Benedetti Panici
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s194874
Subject(s) - olaparib , medicine , ovarian cancer , oncology , stage (stratigraphy) , overall survival , chemotherapy , brca mutation , cancer , disease , poly adp ribose polymerase , biology , paleontology , biochemistry , polymerase , gene
Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.